Background: Radiotherapy (RT) is a highly effective anti-cancer treatment forming the standard strategies for brain metastasis in non-small cell lung cancer (NSCLC) patients, but local and distal disease recurrence remains a major cause of mortality. RT is known to enhance tumor immunogenicity and T cell receptor (TCR) repertoire diversity. however, the genomic evolution and mechanisms of RT induced immune responses are unknown. Method: Here, we perform targeted deep sequencing of circulating tumor DNA (ctDNA) on peripheral blood samples and cerebrospinal fluid (CSF) samples collected prior to and during brain radiotherapy from 13 NSCLC patients with brain metastasis. We used a panel to identify cancer-associated gene mutations and analyze tumor mutation burden. We applied next-generation sequencing (NGS) to investigate the T-cell receptor (TCR) repertoire. Results: In this study, we showed that patients with high blood TMB (high >10 mutations/Mb) tended to benefit from brain radiotherapy both in the terms of clinical outcomes of brain lesions and lung lesions. High TMB of CSF was correlated with a favorable clinical efficacy of brain. Response to therapy indicated according to the changes of ctDNA level between baseline and 28 days post-treatment was consistent with clinical outcomes of lung lesions measured by thoracic CT. Moreover, we showed that the low overlap of TCR repertoire in paired blood samples (base to T0) was detected in patients with partial relief (PR), and high overlap of TCR repertoire was in patients with disease stable (SD). Within 24h post-therapy, a high degree of TCR overlap in peripheral blood and CSF was observed from patients with PR in lung lesions, and a low degree of TCR overlap was from patients with SD in lung lesions. Conclusion: These data demonstrated the potential of ctDNA analysis to be a sensitive tool for predicting treatment responsivity, and the level of TCR repertoire overlap correlated with clinical outcomes. Keywords: ctDNA, TCR, NSCLC brain metastasis, clinical outcomes P098 LOC440416lncRNA-Mediated Cell Cycle Arrest Regulated Crizotinib-Induced Hepatotoxicity X. Chen Department of Medical Oncology, Hangzhou First People's Hospital, Hangzhou/CN Background: To evaluate crizotinib-induced hepatotoxicity in mice and investigate the action and role of cell cycle arrest mediated by LOC440416lncRNA during liver injury, furthermore, to provide experiment evidence for screening available hepar protector and expending the clinical application of crizotinib. Method: The levels of blood serum ALT, AST, LDH were detected using ICR mouse model. Liver samples of mouse fixed were stained with hematoxylin and eosin for histopathological analysis. The cell inhibition rate of primary hepatocytes was detected by MTT assay. Cell cyclin distribution and apoptosis were detected by FCM and the expressions of cyclinB1, CDK1, c-PARP and c-caspase-3 were detected with West blotting. LncRNAs regulating hepar cell cycle arrest were screened using Microarray Chip technique after primary hepatocytes were treated with 5mM crizotinib for 24h. The expressions of cell cyclin protein cyclin B1 and CDK1 were tested with West blotting, after siRNA gene silencing technology was used to knock down
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